authors
- Richter, S
- Gan, HK
- MacKenzie, MJ
- Hotte, Sebastien
- Mukherjee, Som
- Kollmannsberger, CK
- Ivy, SP
- Fernandes, K
- Halford, R
- Massey, C
- Wang, L
- Moore, MJ
- Sridhar, SS
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2011
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal